BioAgilytix buys Australia-based 360biolabs
US-based contract research laboratory BioAgilytix Labs has signed a definitive agreement to purchase 360biolabs, the most comprehensive contract research organisation in Australia. The transaction will expand BioAgilytix’s global footprint into jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds further capacity by joining 360biolabs’ internationally recognised quality systems in Melbourne, Victoria with BioAgilytix’s existing laboratories in Durham, North Carolina; Boston, Massachusetts; and Hamburg, Germany. 360biolabs offers world-class virology and immunology expertise, with BSL 2 and 3 laboratories, biomarker and immune monitoring capabilities with a state-of-the-art flow cytometry suite, molecular biology PCR suite and expansive bioanalytical LC-MS/MS small molecule capabilities. 360biolabs aims to build a global specialty laboratory, providing support to enable future medicines for human health with an international presence in the US and Europe to expand and support clinical development programs. The Burnet Institute, global medical research, and public health organisation is a cofounder and majority shareholder of 360biolabs.